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Recent research governance documents say that the body of research evidence must 
reflect population diversity.  The response to this needs to be more sophisticated than 
simply ensuring minorities are present in samples.   
 
For quantitative research looking primarily at treatment effects of drugs and devices I 
make four suggestions.  First, identify where the representation of minorities in 
samples matters (for example, where ethnicity may cause different treatment effects). 
Second, where the representation of a particular group matters then sub-group 
analysis of the results will usually be necessary.  Third, ensuring representation and 
sub-group analysis will have costs; deciding on whether such representation is 
worthwhile will involve cost-benefit analysis.  Fourth, the representation of minorities 
should not be seen as mainly a locality issue.   
 
For qualitative research I argue that the representation of diversity is often important.  
However, given the small samples of many qualitative projects, the best way to ensure 
representation occurs is to allow a proliferation of such research, not to stipulate such 
representation in samples. 
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Introduction 
Paragraph 2.2.7 of the Research Governance Framework for Health and Social Care 
[henceforth, RGF 2.2.7] states (1), 
“Research and those pursuing it should respect the diversity of human culture and 
conditions and take full account of ethnicity, gender, disability, age and sexual 
orientation in its design, undertaking, and reporting.  Researchers should take account 
of the multi-cultural nature of society.  It is particularly important that the body of 
research evidence available to policy makers reflects the diversity of the population.” 
 
The companion document, Governance Arrangements for Research Ethics 
Committees, recommends the provision of information for research participants in 
languages other than English as a “locality issue” for Local Research Ethics 
Committees (LRECs) (2).  It also charges all Research Ethics Committees, both 
LRECs and Multi-centre Research Ethics Committees (MRECs) with the task of 
reassuring themselves concerning  “the characteristics of the population from which 
the research participants will be drawn (including gender, age, literacy, culture, 
economic status and ethnicity) and the justification for any decisions made in this 
respect.” (3). 
 
These recommendations arise from a concern that the ethnic and cultural mix of 
research participants differs from that of the general population.  For example, the 
most recent census indicated that around 90% of the population of England and Wales 
see themselves as white whilst around 10% do not (4).  Figures from the USA suggest 
that there is under representation of some groups in research samples; African-
Americans and Hispanics are amongst these groups (5).  It is thought that a similar 
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situation exists in the UK, with, for example, people of Asian and West Indian origin 
underrepresented; there is some research to support this view (6). 
 
Mastroianni et al give evidence from the USA that women are underrepresented in 
research samples (7).  They suggest that the desire to protect the fetus in the light of, 
for example, the thalidomide scandal, has resulted in women who are, or could 
become, pregnant being excluded from studies.  Children (8) and the elderly (9) have 
also been excluded from samples.  Again, the desire to protect research participants 
may be a factor here.  However, there may also be less noble reasons, such as the 
exclusion of the elderly in order to test drugs on those in whom one is most likely to 
see beneficial effects and least likely to see harmful ones. 
 
Anecdotally it seems that thus far RECs have interpreted the guidelines on diversity 
largely to mean that documents should be translated for use in localities where a high 
proportion of the population do not have English as a first language.  They could set 
more rigorous requirements, however.  They might request translators be available for 
interviews.  They could also request the specific targeting of a population, such as gay 
men, in order to ensure the sample reflects cultural diversity.   
 
In this article I argue that the response of RECs and researchers to RGF 2.2.7 needs to 
be more sophisticated.  Simply ensuring that groups are present in samples is 
inadequate.  I begin by suggesting that what is at the heart of the concern about the 
proportionate representation of diverse groups in research samples is something to do 
with fairness.  I go on to argue that exclusion from the simple participation in research 
is not unfair in itself.  The real concern is that the results of research from which 
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minorities are excluded will not necessarily be applicable to those minorities.   It is 
this that would be unfair.  I then examine the extent to which exclusion from taking 
part in research results in exclusion from the benefits of its results. 
 
Fairness and taking part in research 
The underlying thought of RGF 2.2.7 is that it is unfair for minorities not to be 
represented in research.   In this context, “fairness” concerns distributive justice.  The 
idea of this is that society’s members should get their fair share of its burdens and 
benefits (10).  For example, unemployment is one of society’s burdens.  Thus that, 
say, Afro-Caribbeans are disproportionately unemployed is prima facie unfair and a 
cause for concern.  Similar arguments apply in relation to the burden of imprisonment 
and the benefit of further education.   
 
Is being excluded from research samples a similar cause for concern?  I shall divide 
this question into two further ones.  First, I shall ask whether simply taking part in 
research projects is a benefit of which excluded minorities are unfairly deprived.  
Second, I shall ask whether this exclusion might lead to minorities being deprived of 
the benefits of the research results. 
 
In answering both questions it is useful to divide research projects into two broad 
groups, quantitative and qualitative studies.  Quantitative studies, such as randomised 
controlled trials, are usually concerned primarily with the effects of different 
treatments, such as drugs or devices.  They ask questions such as whether treatment A 
is better than treatment B in terms of an endpoint, such as mortality or morbidity.  
These endpoints can be measured in figures; statistical work can then deliver an 
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answer to the overall research question.  Qualitative studies, by contrast, gather data 
that is primarily verbal rather than numerical.  Their focus is on social phenomena of 
which the researcher is trying to develop an understanding.  This division is a 
simplification.  For example, it is possible to do quantitative research into social 
phenomena and qualitative research into treatments.  However, I do not think the 
simplification masks any important ethical issues.   
 
In the case of quantitative research it seems unlikely that groups excluded from, say, a 
trial comparing a new treatment are missing out on a benefit.  Clearly, those in the 
trial stand a chance of benefiting from a new, better treatment; but the treatment could 
turn out to be worse.  Qualitative research is almost always non-therapeutic or, to use 
the preferred language of the latest Helsinki declaration, it confers neither possible 
great benefit nor great harm (11).  This being the case it is clear that those excluded 
from such research are not being deprived of a benefit and, as such, are not suffering 
unfairness. 
 
There is, of course, the Hawthorne effect (12); as a rule, participants in research 
projects do better than non-participants, whatever the research and whatever arm of 
that research the participants are in.  However, the Hawthorne effect is fairly small 
and its existence is hardly sufficient to drive a campaign to ensure research samples 
reflect cultural diversity.  At most it would seem to imply only that we should recruit 
as many participants as possible, whatever their cultural background.   
 
Thus it seems that the exclusion of a group from taking part in research per se is not 
unfair.  However, this conclusion rests upon an important assumption, that the 
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research itself is ethically sound.  In particular, it is important that the researchers are 
at a point of equipoise or, to use Bayesian terminology, that their prior probabilities 
do not suggest that one arm of the study is significantly superior to another.  If this 
condition were not met then at least two types of problem could emerge.  The first is 
that an un-represented group could be denied cutting edge treatment that we have 
strong grounds to believe superior.  The second is that a represented group could be 
exposed to a risky new treatment that the researchers hope is superior but which we 
have strong grounds to believe may have significant negative effects.  Both types of 
problem appear to have eventuated with research in the USA.  In particular, the 
economically poor (who are often disproportionately from particular ethnic groups) 
are either deprived of treatments, or are used in research for treatments that are then 
only available, once proven effective, to the rich (13).  
  
I conclude, therefore, that the exclusion of groups from taking part in research per se 
is not unfair provided the research itself is ethically sound.  I doubt that this is a 
controversial conclusion.  The more important question is whether such exclusion 
deprives minorities of the benefits of research results.  It is this to which I turn next. 
 
Fairness and the benefits of quantitative research results 
I shall focus first on quantitative research examining the treatment effect of drugs.  
Drugs vary in their effects on individuals.  If they did not, there would be no need for 
large-scale drug trials; one could simply look at the effect on one person and know 
that that effect will apply to all others.  These differences in drug effects are called 
“polymorphism”.  There seem to be three causes of polymorphism (14). 
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The first is environmental: for example, differences in diet (such as the presence of 
high fat or low salt) make some drugs more effective.   
 
The second reason is cultural.  This is closely linked to the first reason.  As an 
example, there may be some cultures in which compliance with drug therapy is an 
issue, or others where there is likely to be the presence of alternative medicines such 
as acupuncture that may disrupt pharmacokinetics, or others where high fat diet is 
present and so forth.   
 
The third reason is genetic.  In particular, people inherit genes that control their liver 
metabolism and can result in them being either slow or fast metabolizers of drugs.  
Slow metabolizers will find a drug less effective and are more likely to experience 
drug toxicity.   
 
Environmental and cultural reasons are probably only markers for a primary cause.  
Thus, when we see a difference in treatment effect based on culture we look for a 
specific behaviour that is the cause of that difference (for example, a high salt diet 
negating the effect of an anti-hypertensive drug).  However, when we see a difference 
based on genes we believe it is the genes themselves that are the cause.  For this 
reason most recent research into polymorphism has centred on genetics as a cause.  
 
There are several types of genetic variability (15).  Race or ethnicity is said to be 
implicated in some of these types such that certain racial or ethnic groups will have 
higher proportions of, say, slow metabolizers than others.  For example, Japanese and 
Inuit populations have a high proportion of rapid acetylation metabolizers; European 
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and African populations have an equal proportion of slow and rapid metabolizers.  
Examples of drugs effected include clonazepam (an anti-epilepsy agent) and the 
stimulant, caffeine. 
 
Thus, we should expect to see differences in the treatment effects of some drugs 
broadly based around racial or ethnic divisions (16).  This gives us grounds to believe 
it would be unfair if the affected ethnic and racial groups were excluded from drug 
research participation.   
 
However, caution is necessary here.  Some American authors have recently 
questioned the idea that racial or ethnic differences based on genetics are likely to be 
the true basis for large differences in treatment effect.  It is already well established 
that the genetic differences between racial groups are minute (17) and that there are 
greater differences within racial groups than between them (18).   
 
From the field of biological anthropology, Marks is scathing concerning the use of 
racial categories as markers for genetic difference (19).  Essentially he argues that 
race is a social construct with no firm basis in the real world and certainly not in 
genetics.  Marks does go on to say, however, that people exhibit genetic variation 
based on geography; they are most like their near neighbours and least like people 
distant from them.  From this it follows that in the case of ethnic groups it is more 
plausible that there will be a genetic line from child to parents to grandparents and so 
on.  As such, genetic differences between ethnic groups may be more marked than 
between racial ones.  The cultural processes that maintain the idea that there exist 
different ethnic groups lead to some genetic differences between those groups (20).   
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Ethnicity is, then, largely a matter of self-perception rather than objective fact.  This 
leads to a further problem of how people end up in particular categories.  For 
example, people categorised as, say, Afro-Caribbean may have very different ethnic 
backgrounds; some may have one “white” parent, for example.  MacBeth looks at 
various attempts to define ethnic groups and concludes that accurate definitions are 
impossible “because of the absence of meaningful boundaries” (21). 
 
Defining someone’s gender is generally less problematic, and the existence of gender-
based polymorphism is fairly well established for some drugs (e.g. alcohol).  Indeed, 
not only do men and women process some drugs differently, women may exhibit 
polymorphism during different stages of the menstrual cycle as well as pre- and post-
menopause (22).  Finally, there is evidence that age is a factor in polymorphism.  
Children (8) and the elderly (23) process drugs differently from other groups. 
 
With these points in place, then, I turn back to RGF 2.2.7 and the question of how 
RECs and researchers should respond to fact that differences in treatment effect are 
present between groups, whatever the reason.  I have a number of suggestions. 
 
1. Identify the research where representation matters. 
In the first place, most of the available research is from the USA and is concerned 
with ethnic and racial groups.  RGF 2.2.7 also picks out other groups, such as those 
based on sexuality, gender and age.  Of these, gender and age are both plausible bases 
for polymorphism.   
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For any research proposal it would seem useful to identify those where it is likely that 
a difference in treatment effect is present.  For example, if one were undertaking 
research into a new anti-anxiety drug of a type like diazepam then it seems plausible 
that the treatment effects will be different for those of Chinese or Japanese origin.  For 
other drugs it will seem unlikely that there will be differences.  Johnson tells us, 
 
“[It] should be possible to identify those drugs most likely to exhibit differences in 
their pharmacokinetics.  For example, a drug which is eliminated entirely by the 
kidneys through filtration and reabsorption and is not highly bound to plasma proteins 
... is highly unlikely to exhibit racial differences in its kinetics.” (24). 
 
Similarly, knowledge of the way groups based on gender or age process drugs should 
allow identification of new products where polymorphism is a possibility.  If, then, 
the research is into a drug where it is highly unlikely that there will be different 
treatment effects amongst particular groups then we should be unconcerned about the 
make-up of the research sample.  The results of the research will apply across all 
groups no matter who were the research participants.   
 
Up to now I have focused on the treatment effects of drugs; I would suggest that the 
argument applies a fortiori to medical devices, where I can think of very few 
examples where one would expect different treatment effects (although age might be a 
factor in some cases, perhaps). 
 
2. If representation matters then proper sub-group analysis is necessary. 
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If there are grounds to expect different treatment effects between groups then simple 
representation in the sample will be insufficient.  If, for example, our sample includes 
3% of an ethnic group for whom treatment effects differ from the rest of the sample 
then this result will be swallowed up by the overall result.  Thus, the researcher will 
need to do a specific sub-group analysis in order to identify the different treatment 
effects.  This has two significant implications for RECs and researchers. 
 
The first is that if an REC specifies that a group be present on a quantitative trial then 
they must also specify that sub-group analysis is done or, at least, that the data is 
collected in such a way that sub-group analysis can be done in the future.  It is 
tokenism to insist on the participation of particular groups unless something is to be 
done with the results.  The second is that the proportion of such groups in the sample 
is irrelevant.  What matters is whether or not there are sufficient numbers to perform 
the sub-group analysis.   
 
There may also be an issue for the Trial Steering committee.  If the REC has specified 
recruitment of particular groups then one task for the committee would be to ensure 
that the necessary recruitment occurs.  This could require targeted recruitment in 
some cases.   
 
(There may be very rare exceptions to this rule.  For example, a researcher might be 
looking at how acetylator status affects the therapeutics of a drug.  She would be 
checking the status of each participant and comparing it against the reaction to a drug.  
In such a case it would be a good idea for the researcher to ensure a high 
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representation of ethnic minorities because this would ensure a wide spread of slow to 
fast acetylators.  But sub-group analysis would be unnecessary.) 
 
3. The decision on whether representation of minorities should be sought will involve 
a judgement of cost and benefit. 
The potential number of groups on whom sub-group analysis could be performed is 
immense.  But obtaining the representation and performing the analysis will cost 
research money.  Simply translating an information sheet into another language will 
be costly, and having an interpreter much more so.  These costs should not be 
imposed unless there is a plausible benefit (as already stated in point 1).  Furthermore, 
such costs should only be imposed if the likely benefit is worthwhile.  As an extreme 
example, seeking Inuit representation in UK samples would seem to give little benefit 
for great cost.  Conversely, seeking the representation of South Asian populations 
would seem worthwhile, but (to restate) only where there is a plausible expectation of 
treatment differences.  More difficult decisions would lie with groups such as those of 
Chinese or Japanese origin, who are not greatly represented in the UK population. 
 
There is at least one other cost implication.  Quantitative trials are powered to give 
results that are statistically significant for the population as a whole.  Where sub-
group analysis is performed then the results may suggest differences between the 
main population and the sub-group, but further research will be necessary to confirm 
these.  Thus a decision must be made whether to power the original research 
sufficiently to do sub-group analysis in the first place, or whether to do further 
research in the light of a suggestive but underpowered result.   
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4. Representation is only partly a locality issue.  At present, ethics committees treat 
the representation of minorities as a locality issue.  Thus, a researcher might be asked 
to provide translated information sheets in an area that has a high proportion of, say, 
South Asians.  There is a danger of this being tokenism.  If minorities are to be 
represented it is because of the potential for differences in treatment effect; this is an 
issue of science.  Scientific matters are not, and should not be, seen as locality issues.   
 
However, there is another sense in which it is reasonable to treat representation as a 
locality issue.  This would be where the researchers or the MREC have identified 
representation of a particular group as scientifically important.  The LREC could then 
say that this group is present in greater than average numbers in their area and that, 
therefore, there should be an effort to enroll them.  But this should not be a matter of 
course.  The LREC in an area with a high proportion of a particular group should not 
insist on its representation in every trial, only in those trials where the group can 
plausibly be expected to experience different treatment effects. 
 
Clearly, representation is not a locality issue for at least two of the other groups 
mentioned in RGF 2.2.7.  One would assume that age and gender differences are 
fairly evenly distributed throughout the population.  The same would not be true of 
economic status and sexuality; however for these types of group it seems very 
unlikely that there will be genetic based differences in treatment effect.  As such, their 
representation is more likely to be of import for qualitative research.  It is to that topic 




Fairness and the results of qualitative research results: Let a thousand flowers 
bloom. 
Factors such as ethnicity, sexuality, gender and economic status are likely to be 
markers for significant cultural differences.  These differences may be of great 
importance for the social phenomena studied by qualitative research.  As such, groups 
excluded from qualitative research may be deprived of its benefits. 
 
A hypothetical example may illustrate this point.  Imagine that a series of interview 
studies suggest that cancer patients like to receive information about their diagnosis 
without family members present.  These studies have been conducted only upon a 
sample that excludes the members of one group who feel very strongly that they want 
family members present when diagnostic information is discussed.  However, the 
interview studies are used to make a policy recommendation; patients should be alone 
when their cancer diagnosis is discussed.  Clearly this disadvantages the un-
represented group. 
 
Thus we have a prima facie case to say that the exclusion of a group from qualitative 
research that has policy implications is unfair.  And whilst most qualitative research is 
small scale and does not have policy implication on its own, each small-scale study 
contributes to an overall picture.  That overall picture will be deceptive and will lead 
to unfair policy decisions. 
 
However, I doubt that the stipulation of particular cultural mixes on samples would be 
an appropriate response to this problem.  The sample sizes in qualitative research are 
often very small; set this alongside the fact that the number of cultures is very great 
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and the impossibility of meeting such a stipulation becomes apparent.  People vary in 
their ethnicity, class, gender, disability, age and sexual orientation, as the Research 
Governance document tells us; they also vary in their class, urban or rural status, and 
in sub-cultures (such as the “drug culture” or the “gun culture”).  Qualitative 
researchers could not reflect such diversity in each of their samples. 
 
In fact, RGF 2.2.7 does not need to be interpreted as requiring such a stipulation.  The 
final sentence tells us,  
  
“It is particularly important that the body of research evidence available to policy 
makers reflects the diversity of the population.” 
 
I suggest the best way to ensure this is simply to encourage qualitative research.  Such 
researchers are curious about the world; left to their own devices, social scientists 
want to examine cultural differences.  A glance through the journal Social Science in 
Medicine should be enough to convince the reader of this.  There are, of course, many 
examples elsewhere (25).  In general if we “let a thousand flowers bloom” in 
qualitative research, then the body of research evidence that reflects the diversity of 
the population will, for the most part, develop.  Where there are gaps then the 
appropriate response would be to commission specific research, not to prevent other 
research. 
 
One caveat is necessary.  Qualitative research is not always small scale.  For example, 
a Government department might commission research into attitudes to organ donation 
with a view to changing the policy from one where it requires consent from relatives 
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to one of presumed consent.  Were groups to be excluded from this study then the 
recommendations that it makes could be entirely inappropriate for them.  In cases 
such as these there seems to be much stronger grounds for RECs to say that the 




This paper has focused on one question, whether research samples should reflect the 
diversity of the population.  This question arose, in part, from RGF 2.2.7.  I have 
suggested that taking account of the multi-cultural nature of society, as RGF 2.2.7 
requires, is not a straightforward matter.  There is a danger of the arbitrary and 
pointless imposition of barriers to both qualitative and quantitative research.  One 
example would be insisting that every research project that takes place in areas with a 
high proportion of some ethnic groups uses translated information sheets.  Such a 
response is inadequate and could be viewed as mere tokenism. 
 
For quantitative research, careful analysis is needed to identify those projects where 
factors such as age, gender or ethnicity may have significant treatment effects.  If the 
analysis confirms that one such factor does, then further thought is needed to decide 
whether the cost of ensuring representation of that group, followed by sub-group 
analysis and possible further research, is worthwhile.  It is perhaps worth adding that 
this issue may gradually fade in importance as treatments come on line that are 
individually tailored rather than based on fairly crude sub-groupings of people (26). 
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For qualitative research, cultural factors will be important in many, perhaps most, 
cases.  But the best way to ensure they are taken into account is to allow the research 
to proliferate and to commission research into neglected areas. 
 
Of course, this does not exhaust the issues relating to research and cultural diversity.  
There are a number of questions that follow from, or are related to, the one tackled 
here.  In the first place, if we are to seek the involvement of minorities then how 
should this be done?  Ashcroft et al (27) suggest that there is insufficient research 
evidence available on cultural barriers to, for example, participation in randomized 
controlled trials.  They also suggest there is a need to protect groups from 
inappropriate involvement in research, for example, where language or cultural 
barriers make informed consent unlikely.   
 
There is also a further point: RGF 2.2.7 talks of the need to ensure that available 
research evidence reflects diversity.  One possible interpretation of this is that the 
research evidence should meet the needs of a diverse population.  At present, some 
argue, this does not occur.  For example, some of the needs of women are not met in 
research because the necessary research is not done.  On a global scale, it is said that 
“less than 10% of worldwide health research is devoted to diseases that account for 
90% of the global burden of disease” (28).  These are important issues concerning 
justice.  However, they move beyond the question of research samples to questions of 
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